Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.46 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.45 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | KDM4B | O94953 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281222 | 1.00 | NNMT (0.56) | NNMTMKNK1MKNK2KCNK3KCNK9 | |
| SCHEMBL9952643 | 0.98 | NNMT (0.54) | NNMTMKNK1MKNK2KCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL7022071 | 0.98 | NNMT (0.54) | NNMTMKNK1MKNK2KCNK3KCNK9 | |
| Trifluoroacetic Acid SCHEMBL16761281 | 0.89 | NNMT (0.46) | NNMTMKNK1MKNK2KCNK3KCNK9 | |
| SCHEMBL9952590 | 0.86 | KCNK3 (0.48) | NNMTMKNK1MKNK2KCNK3KCNK9 | |
| SCHEMBL27841468 | 0.85 | KCNK3 (0.52) | NNMTKCNK3KCNK9LOXLOXL2 | |
| SCHEMBL29640109 | 0.83 | KCNK3 (0.55) | NNMTKCNK3KCNK9LOXLOXL2 | |
| SCHEMBL229446 | 0.83 | KDM4C (0.57) | KCNK3KCNK9LOXLOXL2MAPK1 | |
| SCHEMBL29556902 | 0.83 | KDM4C (0.57) | KCNK3KCNK9LOXLOXL2MAPK1 | |
| SCHEMBL12640026 | 0.83 | KCNK3 (0.55) | NNMTKCNK3KCNK9LOXLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077380-B1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI SA (FR) | 2018-07-25 | — | — | EP | claimed |
| US-9776991-B2 | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | SANOFI (FR) | 2017-10-03 | — | — | US | claimed |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | claimed |
| US-9580438-B2 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | 4SC DISCOVERY GMBH (DE) | 2017-02-28 | — | — | US | claimed |
| US-20160326146-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI (FR) | 2016-11-10 | — | — | US | claimed |
| EP-3077380-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | Sanofi (FR) | 2016-10-12 | — | — | EP | claimed |
| US-20150158878-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2015-06-11 | — | — | US | claimed |
| WO-2015082474-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI (FR) | 2015-06-11 | — | — | WO | claimed |
| EP-2881390-A1 | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | SANOFI (FR) | 2015-06-10 | — | — | EP | claimed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-1362054-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| WO-2003076416-A1 | OXO AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | claimed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | claimed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | claimed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| WO-2002064599-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| WO-2002064578-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | NNMT 122/4885MKNK1 2996/4885MKNK2 2842/4885 |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | CNKSR1, TYK2, ERBB2 | NNMT 737/4885MKNK1 310/4885MKNK2 407/4885 |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | NNMT 150/4885MKNK1 4362/4885MKNK2 4429/4885 |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | NNMT 1442/4885MKNK1 2077/4885MKNK2 1854/4885 |
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | NNMT 4760/4885MKNK1 4596/4885MKNK2 4438/4885 |
| US-20150158878-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | CHUK, KYNU, BLK | NNMT 1372/4885MKNK1 361/4885MKNK2 519/4885 |
| US-20160326146-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, LTA4H | NNMT 2450/4885MKNK1 4235/4885MKNK2 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.